Yahoo · Nov 9, 2026
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FASubmission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpointPreviously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natura

